A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
NCT06809400
This study is recruiting at 9 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to generate evidence of the safety, tolerability, and pharmacokinetics/pharmacodynamics of IV LY4006896 compared with placebo in healthy participants and participants with Parkinson's disease.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Parkinson Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 30 to 85 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Eli Lilly and Company
- Last updated on ClinicalTrials.gov
- October 14, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- Collaborative Neuroscience Network - CNS · Los Alamitos, CA
- Collaborative Neuroscience Network - CNS · Los Alamitos, CA
Florida · 5
- Aqualane Clinical Research · Naples, FL
- Charter Research · Orlando, FL
- Progressive Medical Research · Port Orange, FL
- Charter Research · The Villages, FL
- K2 Medical Research, LLC · The Villages, FL
Michigan · 1
- QUEST Research Institute · Farmington Hills, MI
Texas · 1
- PPD Development, LP · Austin, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.